|Home | About | Journals | Submit | Contact Us | Français|
In the review of MALT of the prostate performed in the case report published by Koga et al1., the overall majority of these low-grade tumours seems to be of clinical stage IE. Conversely, primary non-Hodgkin lymphomas of the prostate of non-MALT histology appear to have a much higher rate of extraprostatic involvement. Botstwick et al. reported on 22 primary prostate NHL and observed a 50% and 19% of lymph node and spleen involvement, respectively.2
Moreover, the reported 1-year lymphoma specific survival in this series is in heavy contrast of the favourable outcome of MALT prostate patient reported by Koga et al.1 Definitive conclusions about the importance of histology on staging and prognosis cannot however be inferred from these studies, because of the small sample size. Further research regarding the outcome of these patients is justified in the framework of future retrospective studies. As such, the Rare Cancer Network (http://www.rarecancer.net) is currently undertaking a large study of primary low- and high-grade lymphoma of the prostate. Inclusion criteria are the following: i) biopsy-proven non-Hodgkin's lymphoma (NHL) extra nodal of the prostate gland; ii) negative work-up (abdominal-pelvic CT with or without bone marrow aspirate) and iii) minimal follow-up of 6 months.
We invite all investigators to participate to this study that aims to more comprehensively investigate and clarify the staging features and outcome of these exceptional patients.